Core Viewpoint - Investors are evaluating Genpact (G) and Epam (EPAM) to determine which stock is more attractive for value investing [1] Valuation Metrics - Both Genpact and Epam currently hold a Zacks Rank of 2 (Buy), indicating positive earnings estimate revisions for both companies [3] - Genpact has a forward P/E ratio of 11.71, while Epam has a forward P/E of 17.39 [5] - Genpact's PEG ratio is 1.22, compared to Epam's PEG ratio of 2.13, suggesting Genpact may be undervalued relative to its growth expectations [5] - Genpact has a P/B ratio of 3.14, while Epam's P/B ratio is 3.26, further indicating Genpact's relative valuation strength [6] - Based on these valuation metrics, Genpact earns a Value grade of A, while Epam receives a Value grade of C, positioning Genpact as the superior value option [6]

Core Viewpoint - The comparison between The Charles Schwab Corporation (SCHW) and Robinhood Markets, Inc. (HOOD) indicates that SCHW currently presents a better value investment opportunity for investors [1]. Valuation Metrics - SCHW has a forward P/E ratio of 17.80, while HOOD's forward P/E is significantly higher at 43.12 [5]. - The PEG ratio for SCHW is 0.83, indicating a more favorable valuation relative to its expected EPS growth, compared to HOOD's PEG ratio of 1.67 [5]. - SCHW's P/B ratio stands at 4.35, whereas HOOD has a much higher P/B ratio of 11.22, suggesting that SCHW is more undervalued in terms of market value versus book value [6]. Earnings Outlook - SCHW is experiencing an improving earnings outlook, which enhances its attractiveness in the Zacks Rank model, indicating a stronger potential for value investors [7].

Core Viewpoint - New Jersey Resources (NJR) is anticipated to report a year-over-year decline in earnings despite an increase in revenues for the quarter ending December 2025, with actual results being crucial for stock price movement [1][2]. Earnings Expectations - The upcoming earnings report is expected to reveal quarterly earnings of $0.99 per share, reflecting a year-over-year decrease of 23.3%, while revenues are projected to be $514.43 million, representing a 5.3% increase from the previous year [3]. Estimate Revisions - The consensus EPS estimate has been revised down by 8.91% over the last 30 days, indicating a reassessment by analysts regarding the company's earnings outlook [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that the Most Accurate Estimate for NJR is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +1.27%, suggesting a more optimistic view from analysts [12]. Historical Performance - NJR has a history of beating consensus EPS estimates, having done so in the last four quarters, with a notable surprise of +6.67% in the most recent quarter [13][14]. Stock Movement Factors - The stock's movement will depend not only on the earnings results but also on management's commentary during the earnings call, which will influence future earnings expectations [2][15].

Core Viewpoint - Teradyne (TER) is anticipated to report a year-over-year increase in earnings driven by higher revenues, with the actual results having a significant impact on its near-term stock price [1][2]. Earnings Expectations - The upcoming earnings report is scheduled for February 2, and if the results exceed expectations, the stock may rise; conversely, a miss could lead to a decline [2]. - The consensus estimate for Teradyne's quarterly earnings is $1.36 per share, reflecting a year-over-year increase of 43.2%, while revenues are projected to be $968.79 million, up 28.7% from the previous year [3]. Estimate Revisions - The consensus EPS estimate has remained unchanged over the last 30 days, indicating that analysts have not significantly altered their initial projections [4]. - For Teradyne, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -1.57%, suggesting a bearish outlook from analysts [12]. Earnings Surprise History - In the last reported quarter, Teradyne was expected to post earnings of $0.78 per share but actually delivered $0.85, resulting in a surprise of +8.97% [13]. - Over the past four quarters, Teradyne has consistently beaten consensus EPS estimates [14]. Industry Comparison - KLA (KLAC), another player in the Zacks Electronics - Miscellaneous Products industry, is expected to report earnings of $8.82 per share for the same quarter, indicating a year-over-year change of +7.6% and revenues of $3.26 billion, up 6.1% [18][19].

Core Viewpoint - Woodward (WWD) is anticipated to report a year-over-year increase in earnings driven by higher revenues, with the consensus outlook suggesting a positive earnings picture that could influence its stock price in the near term [1][2]. Earnings Expectations - The upcoming earnings report is expected to be released on February 2, with analysts predicting quarterly earnings of $1.63 per share, reflecting a year-over-year increase of +20.7% [3]. - Revenues are projected to reach $891.31 million, which is a 15.4% increase compared to the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised down by 0.04% over the last 30 days, indicating a slight reassessment by analysts [4]. - Despite this revision, the Most Accurate Estimate for Woodward is higher than the Zacks Consensus Estimate, resulting in a positive Earnings ESP of +4.41% [12]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that a positive Earnings ESP reading is a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1 (Strong Buy) [10]. - Woodward currently holds a Zacks Rank of 1, indicating a high likelihood of beating the consensus EPS estimate [12]. Historical Performance - In the last reported quarter, Woodward exceeded the expected earnings of $1.83 per share by delivering $2.09, resulting in a surprise of +14.21% [13]. - Over the past four quarters, Woodward has consistently beaten consensus EPS estimates [14]. Industry Comparison - In contrast, Hexcel (HXL), another player in the Aerospace - Defense Equipment industry, is expected to report earnings of $0.5 per share, reflecting a year-over-year decline of -3.9% [19]. - Hexcel's revenues are projected to be $478.38 million, showing a modest increase of 1% from the previous year [19]. - The consensus EPS estimate for Hexcel has been revised down by 3.7% over the last 30 days, resulting in a negative Earnings ESP of -3.76% [20].

Core Viewpoint - The market anticipates a year-over-year decline in Tyson Foods' earnings despite an increase in revenues when it reports its results for the quarter ended December 2025 [1][3]. Earnings Expectations - Tyson Foods is expected to report quarterly earnings of $1.01 per share, reflecting an 11.4% decrease year-over-year [3]. - Revenue projections stand at $14.12 billion, indicating a 3.7% increase from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised 0.49% higher in the last 30 days, suggesting a slight bullish sentiment among analysts [4]. - The Most Accurate Estimate for Tyson is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +1.49%, indicating a likelihood of beating the consensus EPS estimate [12]. Earnings Surprise History - In the last reported quarter, Tyson exceeded expectations by posting earnings of $1.15 per share against an expected $0.85, achieving a surprise of +35.29% [13]. - Over the past four quarters, Tyson has consistently beaten consensus EPS estimates [14]. Predictive Indicators - A positive Earnings ESP is a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1, 2, or 3 [10]. - Tyson currently holds a Zacks Rank of 3, which, along with the positive Earnings ESP, suggests a high probability of exceeding earnings expectations [12].

The market expects Aptiv PLC (APTV) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2025. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on February 2, might help the stock move higher if these key numbers are bett ...

Core Viewpoint - Twist Bioscience (TWST) is anticipated to report a year-over-year increase in earnings driven by higher revenues, with the actual results being a significant factor influencing its near-term stock price [1][2]. Earnings Expectations - The upcoming earnings report is expected to be released on February 2, with a consensus estimate of a quarterly loss of $0.48 per share, reflecting a year-over-year change of +9.4% [3][11]. - Revenues are projected to reach $101.45 million, which is a 14.4% increase from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has remained unchanged over the last 30 days, indicating that analysts have not significantly altered their initial estimates during this period [4]. - The Most Accurate Estimate for Twist Bioscience is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -1.05%, suggesting a bearish outlook from analysts [11]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive or negative reading can predict the deviation of actual earnings from the consensus estimate, with positive readings being more reliable [8][9]. - Twist Bioscience currently holds a Zacks Rank of 2 (Buy), but the negative Earnings ESP complicates predictions of an earnings beat [11]. Historical Performance - In the last reported quarter, Twist Bioscience was expected to post a loss of $0.40 per share but actually reported a loss of $0.45, resulting in a surprise of -12.50% [12]. - Over the past four quarters, the company has beaten consensus EPS estimates two times [13]. Industry Comparison - Regeneron (REGN), another player in the biomedical and genetics industry, is expected to report earnings of $10.6 per share for the same quarter, indicating a year-over-year change of -12.2% and revenues of $3.82 billion, up 0.7% from the previous year [17][18]. - Regeneron has an Earnings ESP of +1.06% and a Zacks Rank of 1 (Strong Buy), suggesting a higher likelihood of beating the consensus EPS estimate [19].

Core Insights - Zacks Premium provides various tools for investors to enhance their stock market engagement and confidence [1][2] Zacks Style Scores - Zacks Style Scores rate stocks based on value, growth, and momentum, serving as complementary indicators to the Zacks Rank [3] - Stocks receive an alphabetic rating from A to F, with A indicating the highest potential for outperforming the market [4] Value Score - The Value Style Score focuses on identifying undervalued stocks using ratios like P/E, PEG, and Price/Sales [4] Growth Score - The Growth Style Score evaluates stocks based on projected and historical earnings, sales, and cash flow to identify sustainable growth opportunities [5] Momentum Score - The Momentum Style Score assesses stocks based on price trends and earnings outlook changes, helping investors capitalize on upward or downward price movements [6] VGM Score - The VGM Score combines all three Style Scores, providing a comprehensive indicator for investors who utilize multiple investing strategies [7] Zacks Rank and Style Scores - The Zacks Rank is a proprietary model that leverages earnings estimate revisions to guide investors in portfolio creation [8] - Stocks rated 1 (Strong Buy) have historically produced an average annual return of +23.83% since 1988, significantly outperforming the S&P 500 [9] Stock Selection Strategy - For optimal returns, investors should focus on stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B [10] - Stocks with a 3 (Hold) rank should also have Style Scores of A or B to maximize upside potential [10] Company Spotlight: Incyte Corporation - Incyte Corporation, based in Wilmington, DE, is a biopharmaceutical company engaged in developing proprietary therapeutics [12] - Currently rated 3 (Hold) with a VGM Score of A, Incyte has a Momentum Style Score of A and has seen a 1.9% increase in shares over the past four weeks [12][13] - The earnings estimate for fiscal 2025 has been revised upwards, with the Zacks Consensus Estimate now at $6.88 per share, reflecting an average earnings surprise of +14.4% [13]

Core Viewpoint - The Zacks Style Scores provide a framework for investors to evaluate stocks based on value, growth, and momentum, enhancing the decision-making process for stock selection [2][3][7]. Summary by Category Zacks Style Scores - The Zacks Style Scores rate stocks using a grading system from A to F, with A being the highest score indicating a better chance of outperforming the market [3]. - The Style Scores are categorized into four types: Value Score, Growth Score, Momentum Score, and VGM Score, each focusing on different investment strategies [3][4][5][6]. Value Score - The Value Score helps investors identify undervalued stocks by analyzing financial ratios such as P/E, PEG, Price/Sales, and Price/Cash Flow [3]. Growth Score - The Growth Score emphasizes a company's financial health and future growth potential, considering projected and historical earnings, sales, and cash flow [4]. Momentum Score - The Momentum Score assists investors in capitalizing on stock price trends, utilizing metrics like one-week price changes and monthly earnings estimate changes [5]. VGM Score - The VGM Score combines the three Style Scores to identify stocks with attractive value, strong growth forecasts, and promising momentum, serving as a useful indicator alongside the Zacks Rank [6]. Zacks Rank - The Zacks Rank is a proprietary model that leverages earnings estimate revisions to guide investors in building successful portfolios, with 1 (Strong Buy) stocks achieving an average annual return of +23.83% since 1988, significantly outperforming the S&P 500 [7][8]. Stock Example: Stryker (SYK) - Stryker is a leading medical technology company, generating approximately 60% of its sales from MedSurg & Neurotechnology and 40% from Orthopaedics, with about 75% of revenue coming from the U.S. market [12]. - Stryker holds a 3 (Hold) rating on the Zacks Rank and has a VGM Score of B, with a Momentum Style Score of B, indicating potential for investors [13][14].